NSABP 23--INTENSIVE AC+ TAMOXIFEN WITH CONVENTIONAL CMF + TAMOXIFEN IN BREAST CA

点击翻译按钮获取中文摘要

The current study is being conducted to determine whether administering Adriamycin and Cyclophosphamide with or without tamoxifen for four cycles is more effective than administering cyclophosphamide, methotrexate, and 5-fluorouracil for six cycles with or without tamoxifen. Women with node-negative breast cancer and pathological tumor size > 1.0 cm who have undergone lumpectomy or total mastectomy and axillary dissection and whose tumor estrogen receptors have been assayed and found to be < 10 fmol/mg cytosol protein by either the dextran-coated charcoal or sucrose-density gradient methods, or < 15 fmol/mg by the enzyme immunoassay method will be eligible. If the immunocytochemical assay (ER-ICA) is used and is reported as negative, it will also be acceptable. Some form of progesterone-receptor analysis must be performed and the results submitted. Progesterone analysis may include quantitative or qualitative (PR-ICA) methods. Patients will be stratified by age, clinical tumor size, and type of operation.